Workflow
Protagonist Therapeutics(PTGX) - 2025 Q2 - Quarterly Report

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Washington, D.C. 20549 For the transition period from to FORM 10-Q Commission File No. 001-37852 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 PROTAGONIST THERAPEUTICS, INC. For the quarterly period ended June 30, 2025 (Exact name of registrant as specified in its charter) Delaware 98-0505495 (State or oth ...